Impact of Assigning Heart Failure as the Underlying Cause of Death on the Calculation of Premature Mortality Due to Cardiovascular Disease in Spain

Impacto de la asignación de la insuficiencia cardiaca como causa básica de defunción en el cálculo de la mortalidad prematura cardiovascular en España

To the Editor,

The description and detailed evaluation of the extent and distribution of diseases, while recognizing their specific epidemiological and etiological characteristics, are important for establishing strategies to improve the health of the general population.1,2 Disease burden measures the health losses in the population that represent the fatal and nonfatal consequences of diseases and their risk factors. Specifically, the Global Burden of Disease study was the first to establish a standardized measure for measuring premature mortality (years of life lost [YLL]), a component of the synthetic indicator disability-adjusted life-years, which allows assessment of changes in the health of the general population.1–3 We used a classification of disease burden based on an etiological perspective, grouping the codes of the International Classification of Diseases (ICD) into different groups and categories in order to study disease burden. From this perspective, within the category of cardiovascular disease, heart failure (HF) as an underlying cause of death is included in the so-called garbage codes or ill-defined codes.1,4

Applying the methods described in the Global Burden of Disease study, we quantified the potential impact of deaths coded as HF on calculation of YLL due to cardiovascular disease in 2008 in Spain. Mortality data were obtained from anonymized microdata files from the Spanish National Institute of Statistics for deaths coded to ICD-10 codes: 150 (150.0, 150.1, and 150.9). The denominators were obtained from the current population estimates published by the Spanish National Institute of Statistics. Proportional reallocation was conducted by age and sex for deaths assigned to the ill-defined codes group (ICD-10, group R). The YLL attributed to HF were calculated by age and sex groups taking the Princeton West model life table (level 26 modified) as the reference.1 Social values (age-weighted [κ=1] and the discount rate [3%]) were included, as proposed in this methodology.1 All calculations were performed using the GesMor software package. In 2008, there were 126 252 deaths from cardiovascular diseases, of which 17% were attributed to HF (5% of total deaths in Spain). The crude mortality rate due to HF was 46/100 000 (31.6 men and 60.0 women) and rate adjusted to the standard European population was 23.6/100 000 (22.6 men and 23.3 women). Of the total YLL due to cardiovascular disease (504 091), 12% (60 339) were attributed to HF (9% men and 16% women). The proportion of YLL assigned to HF in relation to all cardiovascular diseases increased with age and was higher among women than men in all the age groups studied, reaching 24% of women ≥85 years (Table).

The proportion of deaths due to cardiovascular causes assigned to HF in Spain is higher than that observed in other countries such as

Table

<table>
<thead>
<tr>
<th>Age groups, years</th>
<th>Heart failure</th>
<th>Cardiovascular disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Men</td>
<td>Women</td>
</tr>
<tr>
<td></td>
<td>Deaths</td>
<td>YLL</td>
</tr>
<tr>
<td>&lt;60</td>
<td>452 (2)</td>
<td>8219 (45)</td>
</tr>
<tr>
<td>60-64</td>
<td>193 (17)</td>
<td>1965 (174)</td>
</tr>
<tr>
<td>65-69</td>
<td>253 (28)</td>
<td>1969 (217)</td>
</tr>
<tr>
<td>70-74</td>
<td>491 (59)</td>
<td>2806 (334)</td>
</tr>
<tr>
<td>75-79</td>
<td>920 (129)</td>
<td>3679 (516)</td>
</tr>
<tr>
<td>80-84</td>
<td>1516 (331)</td>
<td>4059 (887)</td>
</tr>
<tr>
<td>≥85</td>
<td>3291 (1099)</td>
<td>4192 (1400)</td>
</tr>
<tr>
<td>Total</td>
<td>7115 (32)</td>
<td>26 890 (119)</td>
</tr>
</tbody>
</table>

YLL, years of life lost.

Data are expressed as No. (rate per 100 000 population).

REFERENCES


http://dx.doi.org/10.1016/j.rec.2013.06.008
as the US (6%), Mexico (8%), and Brazil (10%). Several factors may contribute to these differences, such as the quality of completing death certificates, the autopsy rate, and epidemiological differences. Determining HF etiology is not always easy but is easier in ischemic heart disease than in other heart diseases such as hypertensive heart disease. Therefore, a higher prevalence of ischemic heart disease, as observed in other countries or in men and younger age groups, may help to at least partly explain the lower percentage of deaths assigned to the HF in these population groups.

Despite the recommendation of the World Health Organization that HF should not be assigned as the underlying cause of death, this entity represents a large proportion of cardiovascular mortality in Spain. Given that the main causes of HF in Spain are ischemic and hypertensive heart disease, the use of mortality statistics to calculate YLL may considerably underestimate premature mortality due to these 2 specific causes, an effect that is more marked in the case of women.

Finally, understanding the epidemiology of HF and its risk factors is of great importance to implement interventions and programs that can control its impact on the health of the general population. Thus, efforts should be maintained and intensified to conduct and document an etiologic diagnosis during the patient’s life and to improve the quality of completing the death certificate, so that, whenever possible, the cause is included and an ICD code is assigned to the underlying cause of death.

FUNDING

The authors received research grants from the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (Project PS09/086).

Note

The results of this study were presented at the XXX Scientific Meeting of the Spanish Society of Epidemiology (Santander, October 17-19, 2012) and the European Congress of Epidemiology (EUROEPI 2012; Oporto, September 5-8, 2012). The opinions expressed in this letter are the responsibility of the authors and do not necessarily reflect the views of the organizations for which they work.

Ricard Génova-Maleras,1,2 Nerea Fernández de Larrea-Baz,1 Elena Álvarez-Martín,1,2 Consuelo Morant-Ginestar,1 and Ferrán Catalá-López1,2,∗

1Servicio de Informes de Salud y Estudios, Subdirección de Promoción de la Salud y Prevención, Consejería de Sanidad, Comunidad de Madrid, Madrid, Spain
2Dirección General de Investigación, Formación e Infraestructuras Sanitarias, Consejería de Sanidad, Comunidad de Madrid, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, Spain
3Departamento de Medicina Preventiva y Salud Pública, Universidad Rey Juan Carlos, Madrid, Spain
4Ministerio de Sanidad, Servicios Sociales e Igualdad, Madrid, Spain
5Unidad Docente de Medicina Familiar y Comunitaria Este, Hospital Ramón y Cajal, Madrid, Spain
6División de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain
7Centro Superior de Investigación en Salud Pública (CSISP-FISABIO), Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Conselleria de Sanitat, Generalitat Valenciana, Valencia, Spain

∗Corresponding author: E-mail address: ferran_catala@hotmail.com (F. Catalá-López).

Available online 23 October 2013

REFERENCES


http://dx.doi.org/10.1016/j.rec.2013.06.010